Phosphodiesterase type 5 inhibitors usage and prostate cancer : a match-paired analysis
Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PD...
|Published in:||Translational andrology and urology, Vol. 6, No. 5 (2017), p. 879-882|
|Other Involved Persons:||; ;|
|Item Description:||Date Revised 13.11.2018|
Citation Status PubMed-not-MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
|QR Code:||Show QR Code|